Documentary record · APPROVAL
Zanvastro (zilganersen) approved as the first disease-modifying treatment for Alexander disease
APPROVED
Event date
September 3, 2026
Jurisdiction
United States
Issuing body
U.S. Food and Drug Administration (announced by the sponsor)
Action type
APPROVAL
Lifecycle state
APPROVED
Verification date
15 September 2026
Legal effect
A marketing approval. It does not determine insurance or Medi-Cal coverage, and the product was described by the sponsor as becoming available in the following weeks.
What this establishes
- Ionis Pharmaceuticals announced on 3 September 2026 that FDA approved Zanvastro (zilganersen) for Alexander disease in pediatric and adult patients.
- Zanvastro is an antisense medicine given by intrathecal injection that reduces production of glial fibrillary acidic protein (GFAP).
- The decision came ahead of the 22 September PDUFA goal date reported earlier, and the sponsor reports a Rare Pediatric Disease priority review voucher.
What this does not establish
- Coverage by any payer.
- Long-term outcomes beyond the trial evidence supporting approval.
- FDA’s own action notice text, which this record has not yet read; the approval is recorded from the sponsor’s announcement.
Why it matters
A first approved treatment for an ultra-rare disease is a regulatory milestone and a coverage question at the same time. The two are decided by different institutions.
Primary source
Related on this site
Register: the record store · record id fda-zanvastro-alexander-disease-2026-09-03.